- FDA approves Novartis drug for high blood pressure treatment
- New cardiovascular risk calculator now available online
- Adherence among chronic disease patients can lead to big savings
- Pfizer forms licensing agreement with Seattle Genetics
- Walgreens puts its money where its mouth is with World AIDS Day campaign
PARSIPPANY, N.J. — A drug made by Daiichi-Sankyo was safe and effective in maintaining reductions in blood pressure in older patients, according to a new study presented at the American Society of Hypertension’s 26th annual meeting in New York.
The “TRINITY” study of Tribenzor (olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide) showed the drug was well-tolerated and effective in patients ranging in age from younger than 65 years to older than 65 years, after a year.
“Older patients generally have a more difficult time achieving recommended blood pressure levels and as a result, their hypertension often remains uncontrolled,” University of Alabama medical professor Suzanne Oparil said. “However, this analysis shows that long-term blood-pressure control can be achieved safely and effectively across all studied dosing strengths with a triple combination therapy regardless of age.”